• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

ALSA Ventures launches European biotech clinical accelerator ‘Eclipse’

Bioengineer by Bioengineer
October 13, 2020
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

ALSA Ventures, a London based European biotech investment firm today announced the launch of Eclipse, a novel clinical development accelerator focused on therapeutics assets in late preclinical development.

IMAGE

Credit: ALSA Ventures

London, UK – ALSA Ventures, a London based European biotech investment firm today announced the launch of Eclipse, a novel clinical development accelerator focused on therapeutics assets in late preclinical development.

ALSA Ventures CEO Alek Safarian said:

“Our model is to work very closely with management teams we invest in. We have considerable bench strength in clinical development experience within the ALSA team, so launching this Accelerator makes a lot of sense on a number of levels.”

Under the Eclipse framework, eligible companies will be selected for equity investment and funding through ALSA’s inaugural fund, ALSA Ventures I SCSp. Applications will be assessed on a competitive basis quarterly, with equity investment of up to $5M offered to awarded companies. Upon receipt of this investment, awarded companies will work with global clinical research organisation ICON to progress their asset through first-in-man studies.

“We are very pleased to have ICON, a leading global provider of outsourced clinical services, support the Eclipse initiative with capabilities across the full spectrum of consulting and clinical development services,” said Safarian.

The Eclipse development programme will invest in novel therapeutic drugs that aim to solve high unmet need, and will focus on scientific innovation in the UK and Europe.

To learn more about the application process and how the Eclipse model works visit: https://www.alsaventures.com/eclipse/summary

###

About ALSA Ventures http://www.alsaventures.com

ALSA Ventures is a UK and EU biotechnology investment firm with a focus on novel therapeutics at preclinical POC or early clinical development stage. The firm was established in 2019, by Alek Safarian, founder and ex-CEO of clinical CRO, Novotech. ALSA Ventures recently announced the first closing of its European biotechnology investment fund, and has made three investments to date.

Media contact:

Susan Fitzpatrick-Napier

[email protected]

Media Contact
Susan Fitzpatrick-Napier
[email protected]

Original Source

https://www.alsaventures.com/eclipse/summary

Tags: BiotechnologycancerClinical TrialsGrants/FundingImmunology/Allergies/AsthmaInfectious/Emerging DiseasesInternal MedicineMedicine/HealthMetabolism/Metabolic Diseasesneurobiology
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Combining Cognitive and Psychodynamic Views on Porn Use

August 6, 2025
Neonatal Care Innovations and Challenges in 21st Century

Neonatal Care Innovations and Challenges in 21st Century

August 6, 2025

Korean Survey of 50,000+ Students Finds Weight Concerns Linked to Increased Depression and Suicidality in Non-Obese Adolescent Girls

August 6, 2025

New Insights into Postpartum Hypertension Care

August 6, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    75 shares
    Share 30 Tweet 19
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Combining Cognitive and Psychodynamic Views on Porn Use

Child-Friendly Audio-Visuals Reduce MRI Anxiety in Kids

Eugenol’s Anti-Leishmanial Potential Explored In Vitro

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.